Medical Use
Inqovi is a combination medication consisting of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor. It is used to treat adult patients with myelodysplastic syndromes (MDS), including both previously treated and untreated cases, as well as de novo and secondary MDS. This includes various French-American-British subtypes and intermediate-1/2 and high-risk groups according to the International Prognostic Scoring System.
Recommended Dosage:
- -Each Inqovi tablet contains 35 mg of decitabine and 100 mg of cedazuridine.
- -The recommended dosage is one tablet taken orally once daily for the first 5 days of each 28-day cycle.
- -Tablets should be taken on an empty stomach, either a couple of hours before or after a meal.
- -After the 5-day treatment period, there is no need to take the medication for the remaining 23 days of the cycle.
- -Take your dose at approximately the same time each day.
- -If you miss a dose by more than 12 hours, skip that dose and extend your cycle by one day.
Warning & Precautions
Do not substitute Inqovi 35 mg-100 mg tablets for an intravenous decitabine product within a treatment cycle. To minimize nausea and vomiting, consider administering antiemetics before each dose.
Perform complete blood cell counts before starting treatment with cedazuridine/decitabine, before each cycle, and as clinically indicated to monitor response and toxicity.
Inqovi (cedazuridine/decitabine) can cause fetal harm if administered to a pregnant woman. Verify pregnancy status in females of reproductive potential before initiating therapy.
Due to the potential for serious adverse reactions in breastfed children, women should not breastfeed during treatment with cedazuridine/decitabine and for at least 2 weeks after the last dose.
Given the genotoxicity findings, males with female partners of reproductive potential should use effective contraception while on treatment with Inqovi tablets and for 3 months after the final dose.
Documentation Availability
Documents required to import INQOVI to India?
INQOVI (Decitabine and Cedazuridine) can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing INQOVI (Cancer Treatment Medicines) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the Generic Name for Inqovi®?
The generic name for Inqovi® is Decitabine and Cedazuridine.
Who manufactures Inqovi®?
Inqovi® is manufactured by Astex Pharmaceuticals, Inc.
Is Inqovi® FDA approved?
Yes, Inqovi® was approved by the FDA on July 7, 2020.
What is Inqovi®?
Inqovi® is an oral combination pill containing decitabine and cedazuridine. Decitabine has long been used to treat myelodysplastic syndromes (MDS), but was previously only available as an intravenous (IV) infusion. Cedazuridine allows Inqovi® to be taken orally. Clinical trials have shown Inqovi® to be effective in some patients with MDS or chronic myelomonocytic leukemia (CMML).
What is the dosage form of Inqovi®?
Inqovi® is supplied as tablets containing 35 mg of decitabine and 100 mg of cedazuridine for oral administration.
How should Inqovi® be taken?
Take one tablet orally once daily for the first 5 days of each 28-day cycle. Tablets should be taken on an empty stomach, at least 2 hours before or after a meal. After the 5-day treatment period, there is no need to take Inqovi® for the remaining 23 days of the cycle.
What are the most common side effects of Inqovi®?
Common side effects include rash, fatigue, hemorrhage, muscle pain (myalgia), constipation, mouth sores (mucositis), joint pain (arthralgia), shortness of breath (dyspnea), diarrhea, nausea, dizziness, fever with low white blood cell count (febrile neutropenia), headache, cough, swelling (edema), decreased appetite, pneumonia, upper respiratory tract infection, and increased liver enzymes (transaminase).
How should Inqovi® be stored?
Store Inqovi® at room temperature between 68°F and 77°F (20°C and 25°C). Keep the tablets in their original blister pack until ready to use.
Is it safe to buy Inqovi® online in India?
Yes, you can safely purchase Inqovi® online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
